IL295741A - Dual aav-myo7a vectors with improved safety for the treatment of ush1b - Google Patents
Dual aav-myo7a vectors with improved safety for the treatment of ush1bInfo
- Publication number
- IL295741A IL295741A IL295741A IL29574122A IL295741A IL 295741 A IL295741 A IL 295741A IL 295741 A IL295741 A IL 295741A IL 29574122 A IL29574122 A IL 29574122A IL 295741 A IL295741 A IL 295741A
- Authority
- IL
- Israel
- Prior art keywords
- polynucleotide
- sequence
- vector
- seq
- aav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/40—Systems of functionally co-operating vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Paper (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pressure Welding/Diffusion-Bonding (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003774P | 2020-04-01 | 2020-04-01 | |
| PCT/US2021/025281 WO2021202817A1 (en) | 2020-04-01 | 2021-03-31 | Dual aav-myo7a vectors with improved safety for the treatment of ush1b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295741A true IL295741A (en) | 2022-10-01 |
Family
ID=77929961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295741A IL295741A (en) | 2020-04-01 | 2021-03-31 | Dual aav-myo7a vectors with improved safety for the treatment of ush1b |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12377169B2 (enExample) |
| EP (1) | EP4126071A4 (enExample) |
| JP (1) | JP7785359B2 (enExample) |
| CN (1) | CN115666658A (enExample) |
| AU (1) | AU2021247172A1 (enExample) |
| CA (1) | CA3174500A1 (enExample) |
| IL (1) | IL295741A (enExample) |
| WO (1) | WO2021202817A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12359221B2 (en) | 2017-05-05 | 2025-07-15 | The Regents Of The University Of California | Compositions and methods for expressing otoferlin |
| WO2020093018A1 (en) | 2018-11-01 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | A codon optimized otoferlin aav dual vector gene therapy |
| EP3921032A4 (en) | 2019-02-08 | 2022-11-30 | Decibel Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS |
| TWI896570B (zh) | 2019-10-30 | 2025-09-11 | 美商迪賽博治療公司 | 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法 |
| US20240167056A1 (en) * | 2022-05-09 | 2024-05-23 | Akouos, Inc. | Cell specific gene therapy delivery compositions and methods for treating hearing loss |
| CN116925239B (zh) * | 2023-07-17 | 2024-10-18 | 苏州星奥拓维生物技术有限公司 | 双载体系统表达Otof基因的组合物和方法 |
| WO2025153705A1 (en) * | 2024-01-18 | 2025-07-24 | Splicebio, Sl | Use of split intein for the treatment of myo7a-associated disease |
| CN120400250A (zh) * | 2024-02-01 | 2025-08-01 | 苏州星奥拓维生物技术有限公司 | 表达myo7a蛋白的双载体系统及其用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4445701A (en) | 2000-03-24 | 2001-10-03 | Centre National De La Recherche Scientifique-Cnrs | Multiple human and mouse otoferlin isoforms |
| EP2434020B1 (en) | 2004-01-22 | 2014-11-05 | Dnavec Research Inc. | Method of producing Paramyxoviridae viral vectors using a hybrid promoter comprising a cytomegalovirus enhancer and a chicken beta-actin promoter |
| US8298818B2 (en) | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| WO2008088895A2 (en) | 2007-01-18 | 2008-07-24 | University Of Missouri-Columbia | Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma |
| FR2919305B1 (fr) | 2007-07-26 | 2009-09-18 | Genethon Ass Loi De 1901 | Vecteurs viraux adeno-associes pour l'expression de la dysferline. |
| US8236557B2 (en) | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| WO2010062905A2 (en) | 2008-11-26 | 2010-06-03 | The Regents Of The University Of California | Lateral ventricle cell compositions and use for treating neural degenerative diseases |
| HUE041571T2 (hu) | 2010-04-23 | 2019-05-28 | Univ Florida | RAAV-guanilát-cikláz-készítmények és ejárások 1-es típusú Leber-féle veleszületett vakság (LCA1) kezelésére |
| WO2013075008A1 (en) | 2011-11-16 | 2013-05-23 | University Of Florida Research Foundation Inc. | Aav dual vector systems for gene therapy |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| CN105209619B (zh) | 2013-03-11 | 2018-10-12 | 泰莱托恩基金会 | miR-204和miR-211及其用途 |
| DK2986635T3 (en) | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| KR102298579B1 (ko) | 2013-05-21 | 2021-09-07 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 |
| US11000597B2 (en) | 2015-01-21 | 2021-05-11 | University Of Florida Research Foundation, Incorporated | Engineered receptor/ligand system for delivery of therapeutic agents |
| US10751385B2 (en) | 2015-02-20 | 2020-08-25 | Institut Pasteur | Prevention and/or treatment of hearing loss or impairment |
| CA2979120A1 (en) | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof |
| CN107112767B (zh) | 2015-06-30 | 2019-06-07 | 深圳市大疆创新科技有限公司 | 充电控制电路、充电装置、充电系统及充电控制方法 |
| AU2016324317A1 (en) | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
| CA3007476A1 (en) | 2015-12-11 | 2017-06-15 | Massachusetts Eye And Ear Infirmary | Materials and methods for delivering nucleic acids to cochlear and vestibular cells |
| EP3393522B1 (en) * | 2015-12-22 | 2021-07-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved hybrid dual recombinant aav vector systems for gene therapy |
| AU2017286623A1 (en) * | 2016-06-15 | 2018-12-20 | Oxford University Innovation Limited | Dual overlapping adeno-associated viral vector system for expressing ABC4A |
| WO2018039375A1 (en) | 2016-08-23 | 2018-03-01 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
| MA47820A (fr) | 2017-03-10 | 2020-01-15 | Genethon | Traitement de la glycogénose de type iii |
| US12359221B2 (en) | 2017-05-05 | 2025-07-15 | The Regents Of The University Of California | Compositions and methods for expressing otoferlin |
| IL325122A (en) | 2018-02-22 | 2026-02-01 | Akouos Inc | Compositions and methods for treating non-age-related hearing impairment in humans |
| CA3094828A1 (en) * | 2018-03-23 | 2019-09-26 | Massachusetts Eye And Ear Infirmary | Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome |
| WO2020093018A1 (en) | 2018-11-01 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | A codon optimized otoferlin aav dual vector gene therapy |
| CN113924109A (zh) | 2019-01-18 | 2022-01-11 | 巴斯德研究所 | Aav介导的基因疗法恢复耳畸蛋白基因 |
| TWI896570B (zh) | 2019-10-30 | 2025-09-11 | 美商迪賽博治療公司 | 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法 |
| CA3168055A1 (en) | 2020-02-21 | 2021-08-26 | Emmanuel John Simons | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
-
2021
- 2021-03-31 IL IL295741A patent/IL295741A/en unknown
- 2021-03-31 EP EP21781660.2A patent/EP4126071A4/en active Pending
- 2021-03-31 AU AU2021247172A patent/AU2021247172A1/en active Pending
- 2021-03-31 US US17/916,308 patent/US12377169B2/en active Active
- 2021-03-31 JP JP2022560108A patent/JP7785359B2/ja active Active
- 2021-03-31 WO PCT/US2021/025281 patent/WO2021202817A1/en not_active Ceased
- 2021-03-31 CN CN202180032038.5A patent/CN115666658A/zh active Pending
- 2021-03-31 CA CA3174500A patent/CA3174500A1/en active Pending
-
2025
- 2025-06-23 US US19/245,523 patent/US20250381298A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230149565A1 (en) | 2023-05-18 |
| JP2023520488A (ja) | 2023-05-17 |
| WO2021202817A1 (en) | 2021-10-07 |
| EP4126071A1 (en) | 2023-02-08 |
| CN115666658A (zh) | 2023-01-31 |
| CA3174500A1 (en) | 2021-10-07 |
| US20250381298A1 (en) | 2025-12-18 |
| EP4126071A4 (en) | 2024-05-08 |
| JP7785359B2 (ja) | 2025-12-15 |
| AU2021247172A1 (en) | 2022-09-15 |
| US12377169B2 (en) | 2025-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11325956B2 (en) | Dual-AAV vector-based systems and methods for delivering oversized genes to mammalian cells | |
| US20250381298A1 (en) | Dual aav-myo7a vectors with improved safety for the treatment of ush1b | |
| US12571002B2 (en) | Gene therapies for lysosomal disorders | |
| US20250121092A1 (en) | Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases | |
| US10308957B2 (en) | rAAV vectors and methods for transduction of photoreceptors and RPE cells | |
| US20170007720A1 (en) | Methods and compositions for gene delivery to on bipolar cells | |
| JP2019500039A (ja) | 遺伝子治療用の改良された複合型二重組換えａａｖベクターシステム | |
| KR102892243B1 (ko) | 21-하이드록실라제 결핍을 위한 아데노-관련 바이러스 유전자 요법 | |
| WO2024229049A1 (en) | Dual aav vectors for treating stargardt disease | |
| WO2026085386A1 (en) | Methods for treating xlrs | |
| JP2024515612A (ja) | 球脊髄性筋萎縮症（ｓｂｍａ）の治療に有用な組成物 | |
| WO2025217117A1 (en) | Compositions with cardiac and skeletal muscle-specific targeting motifs and uses thereof | |
| CA3008264A1 (en) | Gene therapy for ocular disorders |